Full Press Release Details
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)
Please find enclosed a Press Release on
"Dr. Reddy's to release Q4 and full year FY 22 results on May 19th, 2022 Earnings call slated for May 19th @ 5:30 PM IST
This is for your information.
For Dr. Reddy's Laboratories Limited
| /s K Randhir Singh | |
| K Randhir Singh | |
| Company Secretary & Compliance Officer |
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS |
| 8-2-337, Road No. 3, Banjara Hills, | ||
| Hyderabad - 500034, Telangana, India. | AMIT AGARWAL | USHA IYER |
| amita@drreddys.com | ushaiyer@drreddys.com |
Reddy's to release Q4 and full year FY 22 results on May 19th, 2022
call slated for May 19th @ 5:30 PM IST / 8:00 AM EDT
Hyderabad, India, April 25th, 2022
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:
RDY, NSEIFSC: DRREDDY) will announce results for the fourth quarter and full year ended March 31st, 2022 on Thursday,
May 19th, 2022 after the Board Meeting.
| Event | Date and Time | Medium | ||
| Release of financial results | May 19 th , after the Board Meeting | Stock Exchange, Media, Company website, Business wire, Email | ||
| Press meet presentation | Will be available on the Company's website | Company's website www.drreddys.com | ||
| Earnings Call | May 19 th , 5:30 PM IST / 8:00 AM EDT | Hosted by the Company (Details below) | ||
| Playback of Earnings Call | After the earnings call till May 25 th , 2022 | Details below | ||
| Transcript of the Earnings call | Will be available on the Company's website | Company's website www.drreddys.com |
Following the release, the management of
the Company will host an earnings call to discuss the Company's financial performance. (Dial In and other details given
The play back will be available after the
earnings call, till May 25th, 2022. For play back dial in phone No: +91 22 7194 5757 | +91 22 6663 5757, and Playback
Conference Joining Information
Option 1: Express Join with DiamondPass
Pre-register with the below link and join without waiting for
| Option 2: Join through below Dial-In Numbers | |
| Universal Access Number: | +91 22 6280 1219 +91 22 7115 8120 |
| International Toll Free Number: | USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448 |
No password/pin number is necessary to
dial in to any of the above numbers. The operator will provide instructions on asking questions before and during the call.
About Dr. Reddy's: Dr. Reddy's Laboratories
Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing
affordable and innovative medicines for healthier lives. Through its businesses, Dr. Reddy's offers a portfolio of products
and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major
therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddy's
operates in markets across the globe. Our Major markets include - USA, India, Russia & CIS countries, and Europe. For
more information, log on to: www.drreddys.com
Disclaimer: This press release may include statements
of future expectations and other forward-looking statements that are based on the management's current views and assumptions
and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially
from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the
words "may", "will", "should", "expects", "plans", "intends", "anticipates",
"believes", "estimates", "predicts", "potential", or "continue" and similar expressions
identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements
due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency
exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity
levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and
in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration
issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services
to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus
(or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission,
including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report
on Form 20-F for the year ended March 31, 2021. The company assumes no obligation to update any information contained herein."
The company assumes no obligation to update any information